Semper Maior 2026: Biotech M&A – Inside the Room Where It Happens

In this year’s Semper Maior report, in addition to the usual analysis of how Core Biotech performed, we’ll review the biotech M&A landscape over the past several years, best practices for preparing for M&A, and tips for executing on a deal if and when the time comes. We’ll examine the crucial roles various advisors may play along the way. We’ll take stock of who’s buying, what they’re buying, and why. We’ll share some advice we’ve gleaned from some of the smartest and most connected dealmakers in biotech. A small mistake can be worth an astounding amount considering the many years of value creation that leads up to an exit.